Abstract Library

#3078 Gastroenteropancreatic Neuroendocrine Tumor: Experience of an Algerian Centre

Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NETs) constitute a rare and heterogeneous group of tumors and still constitute a diagnostic and therapeutic challenge.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Aris H, Ghomari S,

Keywords: gastroenteropancreatic neuroendocrine tumor, centre experience, treatment, survival,

#2962 90Y- and/or 177Lu-DOTATOC Re-Challenge in Patients with Progressive Neuroendocrine Tumors

Introduction: Most patients treated with PRRT will eventually progress. Previous studies indicated that repeated PRRT is feasible and promising.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Aberle S

Authors: Aberle S, Benz M, Grokovski R, Christ E, Nicolas G,

Keywords: PRRT, Re-challenge, 90Y-DOTATOC, 177Lu-DOTATOC, neuroendocrine tumor,

#2940 Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated, Grade 3 Neuroendocrine Carcinomas (NECs)

Introduction: Poorly differentiated, G3 NECs are associated with poor outcomes and have no effective treatment options apart from cytotoxic chemotherapy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rodriguez-Freixinos V

Authors: Rodriguez-Freixinos V, Chan D, Doherty M, Wasson K, Iscoe N,

Keywords: Poorly differentiated, G3 NECs, Avelumab, Immunotherapy,

#2843 Metastatic Risk in Pancreatic Neuroendocrine Tumors: A 16-Year Experience from Bogotá, Colombia. A Series Cases

Introduction: Pancreatic neuroendocrine tumors (pNET) are rare, have a wide range of phenotypes, increase incidence in recent years; which represents a challenge in diagnosis, treatment, and follow-up

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: González Devia D

Authors: Guzman Ruiz Y, Vera Torres A, López Panqueva R, Ardila Duarte G, González Devia D,

Keywords: Pancreatic neuroendocrine tumors, Pancreatic tumor, Prognosis, Neuroendocrine tumor, Gastroenteropancreatic tumor,

#2758 Survival According to Therapy Regimen for siNET: Data from 145 Patients from a German Tertiary Referral Centre, Preliminary Results

Introduction: Scarce data exists for therapy regimens other than SSRA and PRRT for siNET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Bambey C, Koch C, Filmann N, Husmann G, Bojunga J,

Keywords: siNET, survival, multimodal therapy,